Close the acquisition of Checkmate Pharmaceuticals, Inc. via tender offer
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 May 2022
- Due
- 30 Jun 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The transaction is expected to close, subject to the satisfaction of customary closing conditions including regulatory approvals, in mid-2022.”
What we found
Evidence strength A What the grades mean
The 10-Q filed 2022-08-03 states the Checkmate acquisition was completed in May 2022, before the mid-2022 deadline; no exact day is given.
-
A Regeneron Pharmaceuticals 10-Q filed 2022-08-03
“In May 2022, the Company completed its acquisition of Checkmate Pharmaceuticals, Inc. for a total equity value of approximately $250 million.” ✓ confirmed on the page
-
A Regeneron Pharmaceuticals 10-Q filed 2022-08-03
“In May 2022, the Company completed its acquisition of Checkmate Pharmaceuticals, Inc. (“Checkmate”) for a total equity value of approximately $250 million.” ✓ confirmed on the page
Market reaction: the shares moved +5.4% against the S&P 500 over the three sessions around the disclosure (2 Aug 2022 to 5 Aug 2022). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- Acquisition of Checkmate Pharmaceuticals, Inc.
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: subject to the satisfaction of customary closing conditions including regulatory approvals
- Depends on
- Regulatory, Shareholder, Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Regeneron Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-REGN-006341 · Corrections policy